https://www.selleckchem.com/pr....oducts/fluzoparib.ht
Crossover between direct oral anticoagulants (DOACs) has been underinvestigated, but happens frequently in clinical practice. It is still unknown whether DOACs have similar rates of switch, or whether some DOACs are more prone to be switched over time. We reviewed studies comparing DOAC-to-DOAC switch prevalence, and compared risk of switch depending on index DOAC through meta-analysis. Systematic review followed PRISMA guidelines and deposited protocol (PROSPERO#crd42020152405). MEDLINE, EMBASE, and Cochrane-CENTRAL were searched up
Like
Comment
Share
